[EN] How to assess the interplay between tumor, microbiota and therapies? A comprehensive platform to investigate bacteria as immuno-modulating vectors or agents.

[EN] How to recruit immune cells against tumor? Bispecific compounds are the key for new oncology therapeutic strategy

Novel fluorescent probes evaluated in an orthotopic pancreatic PDX model

Novel fluorescent probes evaluated in an orthotopic pancreatic PDX model

[EN] How to better predict the effect of cancer immunotherapy? Tailored-made humanized mouse models are the key solution!

Oncodesign and HitGen announce a strategic partnership in Integrated Drug Discovery Services (IDDS)

Bioanalytical challenges with BioChaperone® BC structures

We wish to develop and validate LC-MS/MS methods for the quantitation of both BioChaperone® BCXXX (Parent) and its truncated metabolite BCYYY inSprague-Dawley rat, Beagle dog and human plasma following the current international guidelines for industry?

[EN] How to trigger the immune response in anti-tumor therapy? A comprehensive in vitro to in vivo screening platform to identify ICD inducers

Oncodesign announces the creation of its new “Artificial Intelligence” Business Unit and appoints Stéphane Gerart as its Head

[EN] Simple services or solutions provider: what is the best option to support your drug discovery efforts at preclinical stage?

Outsourcing drug discovery represents a cost-effective opportunity to access specialized technologies & expert scientist resources and provide solutions

Single dose pharmacokinetics of intravenous 3,4-dihydroxyphenylacetic acid and 3-hydroxyphenylacetic acid in rats

Single dose pharmacokinetics of intravenous 3,4-dihydroxyphenylacetic acid and 3-hydroxyphenylacetic acid in rats

Oncodesign and Servier reach a key first milestone in their strategic partnership on LRRK2 inhibitors for Parkinson’s Disease

G Protein-Coupling of Adhesion GPCRs ADGRE2/EMR2 and ADGRE5/CD97, and Activation of G Protein Signalling by an Anti-EMR2 Antibody

G Protein-Coupling of Adhesion GPCRs ADGRE2/EMR2 and ADGRE5/CD97, and Activation of G Protein Signalling by an Anti-EMR2 Antibody